• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $COO

    The Cooper Companies Inc.

    Subscribe to $COO
    $COO
    Ophthalmic Goods
    Health Care

    The Cooper Companies, Inc. operates as a medical device company worldwide. It operates through two segments, CooperVision and CooperSurgical. The company develops, manufactures, and markets a range of contact lenses, including spherical lenses, and toric and multifocal lenses that correct near- and farsightedness, as well as addresses various complex visual defects, such as astigmatism and presbyopia. It also provides range of products and services for enhancing health of women, babies, and families, including medical devices, fertility, genomics, and diagnostics and contraception for hospitals and surgical centers, obstetricians' and gynecologists' (OB/GYNs) medical offices, and fertility clinics. In addition, the company develops mechanical surgical solutions for skin closure; and offers PARAGARD, a contraceptive, as well as provides assisted reproductive technology products, genetic screening and testing, and products within the general OB/GYN offerings. It markets its products under Biofinity, clariti 1day, MyDay, Avaira Vitality, and Proclear 1 Day brand name through a network of field sales representatives, independent agents, eye care practitioners, and distributors. The Cooper Companies, Inc. was founded in 1980 and is headquartered in San Ramon, California.

    IPO Year:

    Exchange: NYSE

    Website: coopercos.com

    Peers

    $CPS

    Recent Analyst Ratings for The Cooper Companies Inc.

    DatePrice TargetRatingAnalyst
    5/30/2025$76.00Overweight → Neutral
    Analyst
    8/29/2024$115.00 → $120.00Overweight
    Piper Sandler
    7/16/2024$107.00 → $115.00Hold → Buy
    Jefferies
    3/19/2024$125.00Neutral → Buy
    Redburn Atlantic
    3/13/2024$100.00 → $120.00Neutral → Overweight
    JP Morgan
    2/6/2024Sector Weight
    KeyBanc Capital Markets
    10/30/2023$380.00Buy
    BofA Securities
    10/5/2023$390.00 → $343.00Overweight → Neutral
    Redburn Atlantic
    5/30/2023$410.00Equal-Weight
    Morgan Stanley
    12/22/2022$375.00Buy
    Mizuho
    See more ratings

    The Cooper Companies Inc. SEC Filings

    See more
    • SEC Form SD filed by The Cooper Companies Inc.

      SD - COOPER COMPANIES, INC. (0000711404) (Filer)

      5/30/25 4:20:18 PM ET
      $COO
      Ophthalmic Goods
      Health Care
    • SEC Form 10-Q filed by The Cooper Companies Inc.

      10-Q - COOPER COMPANIES, INC. (0000711404) (Filer)

      5/30/25 4:19:23 PM ET
      $COO
      Ophthalmic Goods
      Health Care
    • SEC Form 8-K filed by The Cooper Companies Inc.

      8-K - COOPER COMPANIES, INC. (0000711404) (Filer)

      5/29/25 4:31:50 PM ET
      $COO
      Ophthalmic Goods
      Health Care
    • The Cooper Companies Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure

      8-K - COOPER COMPANIES, INC. (0000711404) (Filer)

      4/30/25 4:21:05 PM ET
      $COO
      Ophthalmic Goods
      Health Care
    • The Cooper Companies Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - COOPER COMPANIES, INC. (0000711404) (Filer)

      4/2/25 5:11:06 PM ET
      $COO
      Ophthalmic Goods
      Health Care
    • SEC Form 10-Q filed by The Cooper Companies Inc.

      10-Q - COOPER COMPANIES, INC. (0000711404) (Filer)

      3/7/25 4:22:17 PM ET
      $COO
      Ophthalmic Goods
      Health Care
    • SEC Form 8-K filed by The Cooper Companies Inc.

      8-K - COOPER COMPANIES, INC. (0000711404) (Filer)

      3/6/25 4:29:32 PM ET
      $COO
      Ophthalmic Goods
      Health Care
    • SEC Form DEFA14A filed by The Cooper Companies Inc.

      DEFA14A - COOPER COMPANIES, INC. (0000711404) (Filer)

      2/19/25 4:32:28 PM ET
      $COO
      Ophthalmic Goods
      Health Care
    • SEC Form DEF 14A filed by The Cooper Companies Inc.

      DEF 14A - COOPER COMPANIES, INC. (0000711404) (Filer)

      2/19/25 4:28:50 PM ET
      $COO
      Ophthalmic Goods
      Health Care
    • SEC Form PREM14A filed by The Cooper Companies Inc.

      PREM14A - COOPER COMPANIES, INC. (0000711404) (Filer)

      2/7/25 4:17:45 PM ET
      $COO
      Ophthalmic Goods
      Health Care

    The Cooper Companies Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • CooperCompanies Announces Second Quarter 2025 Results

      SAN RAMON, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading global medical device company, today announced financial results for its fiscal second quarter ended April 30, 2025. Revenue increased 6% year-over-year to $1,002.3 million. CooperVision (CVI) revenue up 5% to $669.6 million, and CooperSurgical (CSI) revenue up 8% to $332.7 million.GAAP diluted earnings per share (EPS) of $0.44, consistent with last year's second quarter.Non-GAAP diluted EPS of $0.96, up $0.11 or 14% from last year's second quarter. See "Reconciliation of Selected GAAP Results to Non-GAAP Results" below. Commenting on the results, Al White, CooperCompanies' President and CEO said,

      5/29/25 4:15:00 PM ET
      $COO
      Ophthalmic Goods
      Health Care
    • CooperCompanies' 2024 Sustainability Report Showcases Efforts that Benefit People and the Planet

      SAN RAMON, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- CooperCompanies ("Cooper") (NASDAQ:COO), a leading medical device company, published its 2024 Sustainability Report. The report showcases the company's initiatives to foster positive change for both people and the planet and provides expanded and updated sustainability performance data. In 2024, CooperCompanies maintained strong partnerships to reduce its plastic footprint, earned a number of sustainability certifications, and supported employee growth with significant investments in learning and development programs for employees. "Our 2024 Sustainability Report reflects Cooper's commitment to help people experience life's beautiful m

      5/20/25 4:15:00 PM ET
      $COO
      Ophthalmic Goods
      Health Care
    • CooperCompanies to Participate in the William Blair Growth Stock Conference

      SAN RAMON, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading global medical device company, announced today it will participate in the William Blair Growth Stock Conference on Thursday, June 5, 2025. Brian Andrews, Executive Vice President, Chief Financial Officer & Treasurer, will represent the Company in a session scheduled at 11:20 AM CT. The webcast will be available to investors and other interested parties by accessing the CooperCompanies' website at http://investor.coopercos.com. About CooperCompaniesCooperCompanies (NASDAQ:COO) is a leading global medical device company focused on helping people experience life's beautiful moments through its two bu

      5/8/25 4:15:00 PM ET
      $COO
      Ophthalmic Goods
      Health Care
    • CooperCompanies Appoints Barbara Carbone to Board of Directors

      SAN RAMON, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading global medical device company, announced today that its Board of Directors has appointed Barbara Carbone as an independent director, effective May 1, 2025. Ms. Carbone has also been appointed to serve on the Audit Committee when she joins the Board. Ms. Carbone brings nearly four decades of experience across a wide variety of industries. She spent most of her career at KPMG LLP, from 1981-2019, where she served more than twenty-four years as an Audit Partner. She served on the KPMG Partnership Audit Committee for six years, including three years as the Chairperson, and as the National Partner in

      4/30/25 4:15:00 PM ET
      $COO
      Ophthalmic Goods
      Health Care
    • CooperCompanies Announces Release Date for Second Quarter 2025

       SAN RAMON, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading medical device company, announced today it will report second quarter 2025 financial results on Thursday, May 29, 2025, at 4:15 PM ET. Following the release, the Company will host a conference call at 5:00 PM ET to discuss the results and current corporate developments. The dial-in number for the call is 800-715-9871 and the conference ID is 1515103. A simultaneous audio webcast and subsequent replay can be accessed at http://investor.coopercos.com. About CooperCompaniesCooperCompanies (NASDAQ:COO) is a leading global medical device company focused on helping people experience life's beautiful

      4/29/25 4:15:00 PM ET
      $COO
      Ophthalmic Goods
      Health Care
    • CooperCompanies Announces First Quarter 2025 Results

      SAN RAMON, Calif., March 06, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading global medical device company, today announced financial results for its fiscal first quarter ended January 31, 2025. Revenue increased 4% year-over-year to $964.7 million. CooperVision (CVI) revenue up 4% to $646.1 million, and CooperSurgical (CSI) revenue up 3% to $318.6 million.GAAP diluted earnings per share (EPS) of $0.52, up $0.11 from last year's first quarter.Non-GAAP diluted EPS of $0.92, up $0.07 from last year's first quarter. See "Reconciliation of Selected GAAP Results to Non-GAAP Results" below. Commenting on the results, Al White, Cooper's President and CEO said, "We started the y

      3/6/25 4:15:00 PM ET
      $COO
      Ophthalmic Goods
      Health Care
    • CooperCompanies Announces Release Date for First Quarter 2025

      SAN RAMON, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO) today announced it will report first quarter 2025 financial results on Thursday, March 6, 2025, at 4:15 PM ET. Following the release, the Company will host a conference call at 5:00 PM ET to discuss the results and current corporate developments. The dial-in number for the call is 800-715-9871 and the conference ID is 7466264. A simultaneous audio webcast and subsequent replay can be accessed at http://investor.coopercos.com. About CooperCompaniesCooperCompanies (NASDAQ:COO) is a leading global medical device company focused on helping people experience life's beautiful moments through its two business unit

      2/3/25 4:15:00 PM ET
      $COO
      Ophthalmic Goods
      Health Care
    • CooperCompanies to Present at the J.P. Morgan Healthcare Conference

      SAN RAMON, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading medical device company, today announced it will participate at the J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025. Al White, President and CEO, will represent the Company in a session scheduled to begin at 6:00 PM ET. A live and archived webcast of this event, where applicable, will be available by accessing the CooperCompanies' website at http://investor.coopercos.com. About CooperCompanies CooperCompanies (NASDAQ:COO) is a leading global medical device company focused on improving lives one person at a time. The Company operates through two business units, CooperVision and Coop

      12/17/24 4:15:00 PM ET
      $COO
      Ophthalmic Goods
      Health Care
    • CooperCompanies Announces Fourth Quarter and Full Year 2024 Results

      SAN RAMON, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading global medical device company, today announced financial results for its fiscal fourth quarter and full year ended October 31, 2024. Fourth quarter 2024 revenue of $1,018.4 million, up 10%, or up 7% organically. Fiscal year 2024 revenue of $3.9 billion, up 8%, or up 8% organically.Fourth quarter 2024 GAAP diluted earnings per share (EPS) of $0.58, up 38%. Fiscal 2024 GAAP diluted EPS of $1.96, up 33%.Fourth quarter 2024 non-GAAP diluted EPS of $1.04, up 19%. Fiscal 2024 non-GAAP diluted EPS of $3.69, up 15%. See "Reconciliation of Selected GAAP Results to Non-GAAP Results" below. Commenting o

      12/5/24 4:15:00 PM ET
      $COO
      Ophthalmic Goods
      Health Care
    • CooperCompanies Announces Release Date for Fourth Quarter and Full Year 2024

      SAN RAMON, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO) today announced it will report fourth quarter and full year 2024 financial results on Thursday, December 5, 2024, at 4:15 PM ET. Following the release, the Company will host a conference call at 5:00 PM ET to discuss the results and current corporate developments. The dial-in number for the call is 800-715-9871 and the conference ID is 2026064. A simultaneous audio webcast and subsequent replay can be accessed at http://investor.coopercos.com. About CooperCompaniesCooperCompanies (NASDAQ:COO) is a leading global medical device company focused on improving lives one person at a time. The Company operates thr

      11/12/24 4:15:00 PM ET
      $COO
      Ophthalmic Goods
      Health Care

    The Cooper Companies Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Carbone Barbara

      4 - COOPER COMPANIES, INC. (0000711404) (Issuer)

      5/5/25 4:16:23 PM ET
      $COO
      Ophthalmic Goods
      Health Care
    • SEC Form 3 filed by new insider Carbone Barbara

      3 - COOPER COMPANIES, INC. (0000711404) (Issuer)

      5/5/25 4:14:05 PM ET
      $COO
      Ophthalmic Goods
      Health Care
    • Director Kozy William A converted options into 2,857 shares, increasing direct ownership by 10% to 31,149 units (SEC Form 4)

      4 - COOPER COMPANIES, INC. (0000711404) (Issuer)

      4/3/25 4:09:38 PM ET
      $COO
      Ophthalmic Goods
      Health Care
    • Director Weiss Robert S converted options into 2,993 shares, increasing direct ownership by 1% to 288,945 units (SEC Form 4)

      4 - COOPER COMPANIES, INC. (0000711404) (Issuer)

      4/3/25 4:09:08 PM ET
      $COO
      Ophthalmic Goods
      Health Care
    • Director Rivas Maria converted options into 2,721 shares (SEC Form 4)

      4 - COOPER COMPANIES, INC. (0000711404) (Issuer)

      4/3/25 4:08:45 PM ET
      $COO
      Ophthalmic Goods
      Health Care
    • Director Madden Teresa S converted options into 2,721 shares, increasing direct ownership by 28% to 12,357 units (SEC Form 4)

      4 - COOPER COMPANIES, INC. (0000711404) (Issuer)

      4/3/25 4:08:24 PM ET
      $COO
      Ophthalmic Goods
      Health Care
    • Director Lucchese Cynthia L converted options into 2,721 shares, increasing direct ownership by 55% to 7,661 units (SEC Form 4)

      4 - COOPER COMPANIES, INC. (0000711404) (Issuer)

      4/3/25 4:07:59 PM ET
      $COO
      Ophthalmic Goods
      Health Care
    • Director Kurzius Lawrence Erik converted options into 2,721 shares, increasing direct ownership by 258% to 3,777 units (SEC Form 4)

      4 - COOPER COMPANIES, INC. (0000711404) (Issuer)

      4/3/25 4:07:32 PM ET
      $COO
      Ophthalmic Goods
      Health Care
    • Director Jay Colleen converted options into 2,721 shares, increasing direct ownership by 10% to 29,521 units (SEC Form 4)

      4 - COOPER COMPANIES, INC. (0000711404) (Issuer)

      4/3/25 4:06:59 PM ET
      $COO
      Ophthalmic Goods
      Health Care
    • SVP & CAO Ricupati Agostino converted options into 2,076 shares and covered exercise/tax liability with 1,055 shares, increasing direct ownership by 15% to 8,020 units (SEC Form 4)

      4 - COOPER COMPANIES, INC. (0000711404) (Issuer)

      4/3/25 4:06:38 PM ET
      $COO
      Ophthalmic Goods
      Health Care

    The Cooper Companies Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by The Cooper Companies Inc. (Amendment)

      SC 13G/A - COOPER COMPANIES, INC. (0000711404) (Subject)

      2/16/24 4:57:01 PM ET
      $COO
      Ophthalmic Goods
      Health Care
    • SEC Form SC 13G filed by The Cooper Companies Inc.

      SC 13G - COOPER COMPANIES, INC. (0000711404) (Subject)

      2/14/24 10:04:33 AM ET
      $COO
      Ophthalmic Goods
      Health Care
    • SEC Form SC 13G/A filed by The Cooper Companies Inc. (Amendment)

      SC 13G/A - COOPER COMPANIES, INC. (0000711404) (Subject)

      2/13/24 5:02:29 PM ET
      $COO
      Ophthalmic Goods
      Health Care
    • SEC Form SC 13G filed by The Cooper Companies Inc.

      SC 13G - COOPER COMPANIES, INC. (0000711404) (Subject)

      2/14/23 12:40:51 PM ET
      $COO
      Ophthalmic Goods
      Health Care
    • SEC Form SC 13G/A filed by The Cooper Companies Inc. (Amendment)

      SC 13G/A - COOPER COMPANIES, INC. (0000711404) (Subject)

      2/14/23 12:37:58 PM ET
      $COO
      Ophthalmic Goods
      Health Care
    • SEC Form SC 13G/A filed by The Cooper Companies Inc. (Amendment)

      SC 13G/A - COOPER COMPANIES, INC. (0000711404) (Subject)

      2/9/23 11:15:26 AM ET
      $COO
      Ophthalmic Goods
      Health Care
    • SEC Form SC 13G/A filed by The Cooper Companies Inc. (Amendment)

      SC 13G/A - COOPER COMPANIES, INC. (0000711404) (Subject)

      2/14/22 2:34:24 PM ET
      $COO
      Ophthalmic Goods
      Health Care
    • SEC Form SC 13G/A filed by The Cooper Companies Inc. (Amendment)

      SC 13G/A - COOPER COMPANIES, INC. (0000711404) (Subject)

      2/9/22 3:43:31 PM ET
      $COO
      Ophthalmic Goods
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - COOPER COMPANIES, INC. (0000711404) (Subject)

      2/16/21 12:23:42 PM ET
      $COO
      Ophthalmic Goods
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - COOPER COMPANIES, INC. (0000711404) (Subject)

      2/16/21 10:55:48 AM ET
      $COO
      Ophthalmic Goods
      Health Care

    The Cooper Companies Inc. Financials

    Live finance-specific insights

    See more
    • CooperCompanies Announces Second Quarter 2025 Results

      SAN RAMON, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading global medical device company, today announced financial results for its fiscal second quarter ended April 30, 2025. Revenue increased 6% year-over-year to $1,002.3 million. CooperVision (CVI) revenue up 5% to $669.6 million, and CooperSurgical (CSI) revenue up 8% to $332.7 million.GAAP diluted earnings per share (EPS) of $0.44, consistent with last year's second quarter.Non-GAAP diluted EPS of $0.96, up $0.11 or 14% from last year's second quarter. See "Reconciliation of Selected GAAP Results to Non-GAAP Results" below. Commenting on the results, Al White, CooperCompanies' President and CEO said,

      5/29/25 4:15:00 PM ET
      $COO
      Ophthalmic Goods
      Health Care
    • CooperCompanies Announces Release Date for Second Quarter 2025

       SAN RAMON, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading medical device company, announced today it will report second quarter 2025 financial results on Thursday, May 29, 2025, at 4:15 PM ET. Following the release, the Company will host a conference call at 5:00 PM ET to discuss the results and current corporate developments. The dial-in number for the call is 800-715-9871 and the conference ID is 1515103. A simultaneous audio webcast and subsequent replay can be accessed at http://investor.coopercos.com. About CooperCompaniesCooperCompanies (NASDAQ:COO) is a leading global medical device company focused on helping people experience life's beautiful

      4/29/25 4:15:00 PM ET
      $COO
      Ophthalmic Goods
      Health Care
    • CooperCompanies Announces First Quarter 2025 Results

      SAN RAMON, Calif., March 06, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading global medical device company, today announced financial results for its fiscal first quarter ended January 31, 2025. Revenue increased 4% year-over-year to $964.7 million. CooperVision (CVI) revenue up 4% to $646.1 million, and CooperSurgical (CSI) revenue up 3% to $318.6 million.GAAP diluted earnings per share (EPS) of $0.52, up $0.11 from last year's first quarter.Non-GAAP diluted EPS of $0.92, up $0.07 from last year's first quarter. See "Reconciliation of Selected GAAP Results to Non-GAAP Results" below. Commenting on the results, Al White, Cooper's President and CEO said, "We started the y

      3/6/25 4:15:00 PM ET
      $COO
      Ophthalmic Goods
      Health Care
    • CooperCompanies Announces Release Date for First Quarter 2025

      SAN RAMON, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO) today announced it will report first quarter 2025 financial results on Thursday, March 6, 2025, at 4:15 PM ET. Following the release, the Company will host a conference call at 5:00 PM ET to discuss the results and current corporate developments. The dial-in number for the call is 800-715-9871 and the conference ID is 7466264. A simultaneous audio webcast and subsequent replay can be accessed at http://investor.coopercos.com. About CooperCompaniesCooperCompanies (NASDAQ:COO) is a leading global medical device company focused on helping people experience life's beautiful moments through its two business unit

      2/3/25 4:15:00 PM ET
      $COO
      Ophthalmic Goods
      Health Care
    • CooperCompanies Announces Fourth Quarter and Full Year 2024 Results

      SAN RAMON, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading global medical device company, today announced financial results for its fiscal fourth quarter and full year ended October 31, 2024. Fourth quarter 2024 revenue of $1,018.4 million, up 10%, or up 7% organically. Fiscal year 2024 revenue of $3.9 billion, up 8%, or up 8% organically.Fourth quarter 2024 GAAP diluted earnings per share (EPS) of $0.58, up 38%. Fiscal 2024 GAAP diluted EPS of $1.96, up 33%.Fourth quarter 2024 non-GAAP diluted EPS of $1.04, up 19%. Fiscal 2024 non-GAAP diluted EPS of $3.69, up 15%. See "Reconciliation of Selected GAAP Results to Non-GAAP Results" below. Commenting o

      12/5/24 4:15:00 PM ET
      $COO
      Ophthalmic Goods
      Health Care
    • CooperCompanies Announces Release Date for Fourth Quarter and Full Year 2024

      SAN RAMON, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO) today announced it will report fourth quarter and full year 2024 financial results on Thursday, December 5, 2024, at 4:15 PM ET. Following the release, the Company will host a conference call at 5:00 PM ET to discuss the results and current corporate developments. The dial-in number for the call is 800-715-9871 and the conference ID is 2026064. A simultaneous audio webcast and subsequent replay can be accessed at http://investor.coopercos.com. About CooperCompaniesCooperCompanies (NASDAQ:COO) is a leading global medical device company focused on improving lives one person at a time. The Company operates thr

      11/12/24 4:15:00 PM ET
      $COO
      Ophthalmic Goods
      Health Care
    • CooperCompanies Announces Third Quarter 2024 Results

      SAN RAMON, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading global medical device company, today announced financial results for its fiscal third quarter ended July 31, 2024. Revenue increased 8% year-over-year to $1,002.8 million. CooperVision (CVI) revenue up 7% to $675.6 million, and CooperSurgical (CSI) revenue up 9% to $327.2 million.GAAP diluted earnings per share (EPS) of $0.52, up $0.09 or 22% from last year's third quarter.Non-GAAP diluted EPS of $0.96, up $0.12 or 14% from last year's third quarter. See "Reconciliation of Selected GAAP Results to Non-GAAP Results" below. Commenting on the results, Al White, Cooper's President and CEO said, "Our

      8/28/24 4:15:00 PM ET
      $COO
      Ophthalmic Goods
      Health Care
    • CooperCompanies Announces Release Date for Third Quarter 2024

      SAN RAMON, Calif., Aug. 06, 2024 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO) today announced it will report third quarter 2024 financial results on Wednesday, August 28, 2024, at 4:15 PM ET. Following the release, the Company will host a conference call at 5:00 PM ET to discuss the results and current corporate developments. The dial-in number for the call is 800-715-9871 and the conference ID is 7528310. A simultaneous audio webcast and subsequent replay can be accessed at http://investor.coopercos.com. About CooperCompaniesCooperCompanies (NASDAQ:COO) is a leading global medical device company focused on improving lives one person at a time. The Company operates through two busine

      8/6/24 4:15:00 PM ET
      $COO
      Ophthalmic Goods
      Health Care
    • CooperCompanies Acquires obp Surgical, Expanding CooperSurgical's Portfolio of Leading Medical Devices

      SAN RAMON, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) --  CooperCompanies (NASDAQ:COO), today announced that CooperSurgical has acquired obp Surgical, a U.S.-based medical device company with a suite of single-use cordless surgical retractors with an integrated multi-LED light source and dual smoke evacuation channels, and single-use surgical suction devices with an integrated, cordless radial LED light source, for approximately $100 million. The products being acquired generated approximately $14.5 million of trailing twelve-month revenue. The acquisition is expected to be neutral to Cooper's non-GAAP earnings per share in fiscal 2024 and accretive thereafter. "This acquisition is a great st

      8/1/24 4:15:00 PM ET
      $COO
      Ophthalmic Goods
      Health Care
    • CooperCompanies Announces Second Quarter 2024 Results

      SAN RAMON, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading global medical device company, today announced financial results for its fiscal second quarter ended April 30, 2024. Revenue increased 7% year-over-year to $942.6 million. CooperVision (CVI) revenue up 8% to $635.9 million, and CooperSurgical (CSI) revenue up 6% to $306.7 million.GAAP diluted earnings per share (EPS) of $0.44, up $0.24 or 122% from last year's second quarter.Non-GAAP diluted EPS of $0.85, up $0.08 or 10% from last year's second quarter. See "Reconciliation of Selected GAAP Results to Non-GAAP Results" below. Commenting on the results, Al White,

      5/30/24 4:15:00 PM ET
      $COO
      Ophthalmic Goods
      Health Care

    The Cooper Companies Inc. Leadership Updates

    Live Leadership Updates

    See more
    • CooperCompanies Appoints Barbara Carbone to Board of Directors

      SAN RAMON, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading global medical device company, announced today that its Board of Directors has appointed Barbara Carbone as an independent director, effective May 1, 2025. Ms. Carbone has also been appointed to serve on the Audit Committee when she joins the Board. Ms. Carbone brings nearly four decades of experience across a wide variety of industries. She spent most of her career at KPMG LLP, from 1981-2019, where she served more than twenty-four years as an Audit Partner. She served on the KPMG Partnership Audit Committee for six years, including three years as the Chairperson, and as the National Partner in

      4/30/25 4:15:00 PM ET
      $COO
      Ophthalmic Goods
      Health Care
    • Evolus Announces Appointment of Albert G. White III to Board of Directors

      Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced the appointment of Albert G. White III, President and Chief Executive Officer of The Cooper Companies, Inc. to the Evolus Board of Directors, effective July 1. Mr. White will also serve as a member of Evolus' Compensation Committee. "We are pleased to welcome Al White to the Evolus Board," said Vik Malik, Chairman of the Board of Directors. "Al's extensive leadership experience, industry knowledge, and proven track record of building a leading medical technology company will be a valuable resource as Evolus embarks on a path from a single-product aes

      7/1/24 8:00:00 AM ET
      $COO
      $EOLS
      Ophthalmic Goods
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • CooperCompanies Appoints Lawrence E. Kurzius to Board of Directors

      SAN RAMON, Calif., Nov. 30, 2023 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO) announced today that its Board of Directors has appointed Lawrence E. Kurzius as an independent director, effective December 1, 2023. Kurzius has also been appointed to serve on the Audit Committee and Organization & Compensation Committee when he joins the Board. "We are thrilled to welcome Lawrence to our Board of Directors," said Al White, President and CEO. "His track record of successfully leading a complex, multinational organization will be extremely valuable to CooperCompanies as we continue to drive global growth at CooperVision and CooperSurgical." Kurzius served as Chief Executive Officer of McCo

      11/30/23 4:15:00 PM ET
      $COO
      Ophthalmic Goods
      Health Care
    • CooperCompanies Appoints Cynthia Lucchese to Board of Directors

      SAN RAMON, Calif., Oct. 03, 2022 (GLOBE NEWSWIRE) -- CooperCompanies (NYSE:COO) announced today that its Board of Directors has appointed Cynthia Lucchese as an independent director, effective October 1, 2022. Lucchese has also been appointed to serve on the Audit Committee and Corporate Governance and Nominating Committee when she joins the Board. "We are pleased to welcome Cindy to Cooper's Board of Directors," said Al White, President and CEO of CooperCompanies. "She is a highly successful executive with a strong strategic, financial, and operational background. We are confident that her business acumen and board experiences will benefit Cooper and our shareholders." Lucchese currentl

      10/3/22 4:15:00 PM ET
      $COO
      Ophthalmic Goods
      Health Care
    • CooperCompanies Appoints Nicholas Khadder as General Counsel and Corporate Secretary

      SAN RAMON, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- CooperCompanies (NYSE:COO) announced today that Nicholas Khadder has been appointed as its general counsel and corporate secretary. Khadder joins Cooper having previously served as general counsel of Standard BioTools Inc. (formerly Fluidigm Corporation) from June 2016 to July 2022. Prior to joining Fluidigm, from 2010 to June 2016, Khadder held various positions at Amyris, Inc., including general counsel and corporate secretary from 2013 to June 2016. Previously, Khadder served in senior corporate counsel roles at LeapFrog Enterprises, Inc. from August 2008 to September 2010, and at Protiviti Inc. (a subsidiary of Robert Half Internati

      8/9/22 4:15:00 PM ET
      $COO
      Ophthalmic Goods
      Health Care
    • CooperVision Appoints Alex Wilkes as President, Americas

      SAN RAMON, Calif., May 23, 2022 /PRNewswire/ -- CooperVision, one of the world's leading manufacturers of contact lenses, has named Alex Wilkes as President, Americas, effective June 14. Wilkes brings more than a decade of experience in the eye care industry, having most recently served as Senior Vice President and General Manager of Pearle Vision at Luxottica. As CooperVision's Americas President, Wilkes will be responsible for driving the growth of the company's largest region.At CooperVision, Wilkes will be responsible for the executive leadership and driving the growth of

      5/23/22 12:00:00 PM ET
      $COO
      Ophthalmic Goods
      Health Care
    • Veev Bolsters C-Suite, Appoints Gordon Heneweer as CFO

      SAN MATEO, Calif., April 04, 2022 (GLOBE NEWSWIRE) -- Today Veev, the technology-enabled homebuilding company, announced the latest addition to its leadership team, naming Gordon Heneweer as Chief Financial Officer. Heneweer will oversee all finance and accounting functions including the Corporate Controllership, FP&A, project finance, Treasury, Tax and business operations, as well as corporate strategy. Veev has achieved a novel approach to homebuilding that views the home as the ultimate consumer product––a highly personal space that should enhance and reflect the lives of the people who live there. Grounded in this consumer-first focus, Veev has pioneered a breakthrough technological a

      4/4/22 9:00:00 AM ET
      $COO
      Ophthalmic Goods
      Health Care
    • Imperative Care Appoints Three to Its Board of Directors

      Holly Sheffield, Medical Technology Executive and Investment Banker Hank Plain, Serial Entrepreneur, Executive and Venture Capital Leader James Rogers, Public and Private Medical Technology Investor Imperative Care, Inc. today announced three appointments to the company's Board of Directors with the addition of Holly Sheffield, Hank Plain, and James Rogers. "We are grateful to have the guidance of Holly, Hank, and James as they bring distinctive and complementary industry leadership to Imperative Care as we continue to accelerate our development and commercialization efforts," said Fred Khosravi, Chairman and CEO of Imperative Care. "Having these high-caliber professionals join our Boar

      8/20/21 8:00:00 AM ET
      $COO
      $OM
      $SGHT
      Ophthalmic Goods
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Medical/Dental Instruments
    • TMRW Appoints Brian E. Miller, Ph.D., as SVP of Sales

      NEW YORK, March 5, 2021 /PRNewswire/ -- TMRW Life Sciences, Inc. ("TMRW"), the creator of the world's first and only automated technology platform for the management, identification, and storage of frozen eggs and embryos, announces today that Brian E. Miller, PhD, is joining TMRW's senior leadership team as Senior Vice President of Sales. In his role, Brian will be responsible for bringing TMRW's innovative technology to fertility clinics in the United States. Brian will also be integral to the ongoing development of new products and services that will expand TMRW's offerings, enabling fertility clinics to further enhance and automate their clinical lab operations. A veteran of the fertilit

      3/5/21 9:00:00 AM ET
      $COO
      Ophthalmic Goods
      Health Care
    • CooperCompanies Declares Cash Dividend

      SAN RAMON, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- CooperCompanies (NYSE: COO), announced today that consistent with the plan approved by its board of directors to pay annual dividends, the Company declared a semi-annual dividend of 3 cents per share, payable on February 9, 2021, to stockholders of record on January 22, 2021. About CooperCompaniesCooperCompanies ("Cooper") is a global medical device company publicly traded on the NYSE (NYSE:COO). Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providin

      1/7/21 4:15:00 PM ET
      $COO
      Ophthalmic Goods
      Health Care

    The Cooper Companies Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cooper downgraded by Analyst with a new price target

      Analyst downgraded Cooper from Overweight to Neutral and set a new price target of $76.00

      5/30/25 8:39:00 AM ET
      $COO
      Ophthalmic Goods
      Health Care
    • Piper Sandler reiterated coverage on Cooper with a new price target

      Piper Sandler reiterated coverage of Cooper with a rating of Overweight and set a new price target of $120.00 from $115.00 previously

      8/29/24 8:24:13 AM ET
      $COO
      Ophthalmic Goods
      Health Care
    • Cooper upgraded by Jefferies with a new price target

      Jefferies upgraded Cooper from Hold to Buy and set a new price target of $115.00 from $107.00 previously

      7/16/24 7:26:08 AM ET
      $COO
      Ophthalmic Goods
      Health Care
    • Cooper upgraded by Redburn Atlantic with a new price target

      Redburn Atlantic upgraded Cooper from Neutral to Buy and set a new price target of $125.00

      3/19/24 7:31:09 AM ET
      $COO
      Ophthalmic Goods
      Health Care
    • Cooper upgraded by JP Morgan with a new price target

      JP Morgan upgraded Cooper from Neutral to Overweight and set a new price target of $120.00 from $100.00 previously

      3/13/24 7:30:41 AM ET
      $COO
      Ophthalmic Goods
      Health Care
    • KeyBanc Capital Markets resumed coverage on Cooper

      KeyBanc Capital Markets resumed coverage of Cooper with a rating of Sector Weight

      2/6/24 6:24:29 AM ET
      $COO
      Ophthalmic Goods
      Health Care
    • BofA Securities initiated coverage on Cooper with a new price target

      BofA Securities initiated coverage of Cooper with a rating of Buy and set a new price target of $380.00

      10/30/23 7:30:11 AM ET
      $COO
      Ophthalmic Goods
      Health Care
    • Cooper downgraded by Redburn Atlantic with a new price target

      Redburn Atlantic downgraded Cooper from Overweight to Neutral and set a new price target of $343.00 from $390.00 previously

      10/5/23 7:26:09 AM ET
      $COO
      Ophthalmic Goods
      Health Care
    • Morgan Stanley initiated coverage on Cooper with a new price target

      Morgan Stanley initiated coverage of Cooper with a rating of Equal-Weight and set a new price target of $410.00

      5/30/23 7:27:38 AM ET
      $COO
      Ophthalmic Goods
      Health Care
    • Mizuho initiated coverage on Cooper with a new price target

      Mizuho initiated coverage of Cooper with a rating of Buy and set a new price target of $375.00

      12/22/22 7:41:19 AM ET
      $COO
      Ophthalmic Goods
      Health Care